首页> 外文期刊>BJU international >Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder.
【24h】

Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder.

机译:凋亡标志物在膀胱鳞状细胞癌中的预后价值。

获取原文
获取原文并翻译 | 示例
           

摘要

Study Type - Prognosis (case series) Level of Evidence 4. What's known on the subject? and What does the study add? Apoptotic pathways are important in carcinogenesis. Many studies, involving small numbers of patients, have found an association between one or two apoptotic markers and some of the pathological features of squamous cell carcinoma (SCC). This study included a large number of patients who had undergone radical cystectomy (RC) for SCC with long-term follow-up, allowing us to study biomarker alterations and their prognostic role. This is the first study on the prognostic role of a panel of apoptotic-related markers in SCC of the urinary bladder, introducing the novel concept of a prognostic marker score based on the number of altered markers. We found that apoptotic markers can improve prediction of oncological outcomes after RC for SCC and might potentially help in patient selection for adjunct therapies.To evaluate the association of cleaved caspase-3 (CC-3), Bax, COX-2, and p53 expression with pathological features and clinical outcomes in patients with squamous cell carcinoma (SCC) of the urinary bladder.Immunohistochemistry for CC-3, Bax, COX-2, and p53 was performed on tissue microarray sections of radical cystectomy specimens with pure SCC from 1997 to 2003. The relationship between the expression of these markers and pathological features was assessed. ? A prognostic marker score (PS) was defined as favourable if ≤2 biomarkers were altered and unfavourable if >2 biomarkers were altered and the association of the PS with oncological outcomes was examined.The study included 151 patients, of whom 98 were men and 53 were women, with a mean age of 52 years. SCC was associated with schistosomiasis (bilharziasis) in 122 (81%) patients. ? Pathological stage was T2 in 50%, T3 in 38%, T1 in 6% and T4 in 6% of patients. Tumours were low grade in 53%, lymph node metastasis was found in 30.5% and lymphovascular invasion was found in 16% of patients. ? Median follow-up was 63.2 months. ? Advanced stage was associated with COX-2, p53 and CC-3 alterations and high grade was associated with COX-2 alterations (P < 0.05). The total number of altered markers and unfavourable PS were associated with both disease recurrence and bladder cancer-specific mortality in Kaplan-Meier analyses (P < 0.05). Unfavourable PS was an independent predictor of disease recurrence (hazard ratio [HR] 2.694, 95% confidence interval [CI] 1.386-5.235, P= 0. 003) and bladder cancer-specific mortality (HR 2.868, 95% CI 1.209-6.802, P= 0. 017) in multivariable Cox regression analysis.Markers of apoptosis pathways may play an important role in the prognosis of SCC of the bladder. An increased number of altered markers and an unfavourable PS may identify patients who might benefit from multimodal therapies.
机译:研究类型-预后(病例系列)证据水平4.关于该学科的知识是什么?该研究增加了什么?凋亡途径在致癌作用中很重要。许多涉及少数患者的研究发现,一种或两种细胞凋亡标志物与鳞状细胞癌(SCC)的某些病理特征之间存在关联。这项研究包括大量接受了SCC根治性膀胱切除术(RC)的患者并进行了长期随访,这使我们能够研究生物标志物改变及其预后作用。这是关于一组凋亡相关标志物在膀胱癌中预后作用的首次研究,介绍了基于改变标志物数量的预后标志物评分的新概念。我们发现,凋亡标记物可以改善RC对SCC的肿瘤结局的预测,并可能有助于选择辅助疗法的患者。评估裂解的caspase-3(CC-3),Bax,COX-2和p53表达的关联在1997年至2004年间,对具有纯SCC的根治性膀胱切除术标本的组织微阵列切片进行了CC-3,Bax,COX-2和p53的免疫组织化学分析,研究了膀胱鳞状细胞癌(SCC)患者的病理特征和临床结局。 2003。评估了这些标志物的表达与病理特征之间的关系。 ?预后标志物评分(PS)被定义为如果≤2个生物标志物被改变是有利的,而如果> 2个生物标志物被改变并被检查与肿瘤学结果的相关性则是不利的。该研究包括151例患者,其中98例男性和53例患者是女性,平均年龄为52岁。 SCC与122名(81%)患者的血吸虫病(胆道病)相关。 ?病理分期为:T2患者占50%,T3患者占38%,T1患者占6%,T4患者占6%。肿瘤为低度,占53%,淋巴结转移为30.5%,淋巴管浸润为16%。 ?中位随访时间为63.2个月。 ?晚期与COX-2,p53和CC-3改变有关,高等级与COX-2改变有关(P <0.05)。在Kaplan-Meier分析中,标志物改变的总数和PS不利与疾病复发和膀胱癌特异性死亡率相关(P <0.05)。 PS不良是疾病复发的独立预测因子(危险比[HR] 2.694,95%置信区间[CI] 1.386-5.235,P = 0.003)和膀胱癌特异性死亡率(HR 2.868,95%CI 1.209-6.802) ,P = 0.017)。在多变量Cox回归分析中。凋亡通路的标记可能在膀胱癌的预后中起重要作用。改变的标志物数量增加和PS不利可能会确定可能从多模式疗法中受益的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号